Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-B2: Alpelisib with trastuzumab and pertuzumab maintenance in HER2-positive advanced breast cancer with PIK3CA mutation
2024-512050-13-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of alpelisib in breast cancer (4 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities in Part 1 and Progression-free survival (PFS) by investigator assessment. Started Jul 2024; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-512050-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512050-13-00.